During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
SheBuysTravel on MSN
I spent four nights at a Miami menopause retreat. Here's what I loved, and what I'm still not sure about
I’m a wife, mom and a globetrotting travel writer. I’m also riding the hormonal rollercoaster of perimenopause. Many of the 1 ...
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...
With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will ...
Share Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 24025 ...
Soefje also discusses the growing role of pharmacists, technology, and comparative efficacy data in improving adherence, ...
Key challenges include logistical hurdles, such as the need for specialized training and infrastructure, and financial ...
Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...
California system riding outpatient wave, John Muir Health, expands infusion services and integrates pharmacists to enhance patient care and convenience.
A nurse-led intervention addressed completion of preinfusion lab tests, improving patient preparedness for infusion, multidisciplinary coordination, and patient outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback